Dry Eye Disease - Pipeline Insight, 2025

DelveInsight’s, “Dry Eye Disease - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Dry Eye Disease: Understanding

Dry Eye Disease: Overview

Dry Eye Disease (DED) is a common ocular condition characterized by insufficient tear production or poor tear quality, leading to discomfort, inflammation, and potential damage to the eye surface. It results from a disruption in the tear film, which can be caused by aging, environmental factors, autoimmune diseases, or prolonged screen time. Symptoms include dryness, burning, redness, blurred vision, and a sensation of grittiness in the eyes. If left untreated, DED can impact daily activities and reduce overall quality of life. With an increasing prevalence worldwide, ongoing research focuses on advanced therapies to improve tear stability and alleviate symptoms.

DED has traditionally been classified into two categories: aqueous deficient and evaporative. These two categories, however, are not mutually exclusive, and numerous patients have a combination of these mechanisms of DED. Aqueous tear deficiency is characterized by inadequate tear production with predominant causes consisting of Sjogren Syndrome (primary or secondary); diseases, inflammation, and/or dysfunction of the lacrimal gland; obstruction of the lacrimal gland; and systemic drugs (i.e., decongestants, antihistamines, diuretics, beta-blockers, etc.) Evaporative dry eye is characterized by increased tear film evaporation and a deficiency in the lipid portion of the tear film. In this case, the quantity of tears produced is normal; however, the quality of tears causes excessive evaporation. This alteration is most frequently caused by meibomian gland dysfunction.

The most common cause of dry eye is a reduction of the aqueous layer through either decreased production from the lacrimal glands or evaporative loss secondary to dysfunction of the other two layers of the tear film. Aqueous production is known to decrease with age, and the immunoglobulin A and lysozyme levels associated with this tear layer also decrease.The posterior layer of the tear film is the mucin layer. Mucin is produced by the goblet cells located in the conjunctival tissue. The mucin layer allows optically smooth layering of the tear film, without break-up because of variable film density or evaporation. Reduction of the goblet cell density from inflammation or trauma can have devastating effects on tear film stability and produce severe dry eye symptoms, even in the presence of epiphora.

Treatment of dry eye syndrome is performed in a step-wise approach that may vary depending on the severity of the disease. Initial approaches include education about the condition, modification of the environment (eliminating direct high airflow/fans, reduced screen time, humidifier), identification and elimination of offending topical and systemic agents, topical ocular lubricants, and lid hygiene (warm compresses and lid scrubs), oral essential fatty acids.

The next step of treatment options includes preservative-free ocular lubricants, reversible punctal occlusion (punctal plugs), night-time ointment or moisture goggles, device-assisted heating and/or expression of the meibomian glands, intense pulsed light therapy, topical anti-inflammatory medications (corticosteroids, cyclosporine, lifitegrast), and oral antibiotics (macrolide or tetracycline).

""Dry Eye Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.

Dry Eye Disease Emerging Drugs Chapters

This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dry Eye Disease Emerging Drugs

AR-15512: Alcon

AR-15512 is an investigational eye drop currently in clinical development at Aerie as a potential treatment for the signs and symptoms of dry eye disease. The active ingredient in AR-15512 is a proprietary small-molecule selective agonist of the transient receptor potential melastatin 8 (TRPM8) cold thermoreceptor, which represents a novel therapeutic target for dry eye. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of DED.

SI-614: Seikagaku Corporation

SI-614, an ophthalmic solution being developed by Seikagaku Corporation. CT-868 is a. SI-614 is an amphiphilic polymer produced by introducing a hydrophobic group into hyaluronic acid using Seikagaku’s own proprietary technology. Ocular instillation of SI-614 in dry eye patients is thought to stabilize the tear film by utilizing the mucoadhesive and surface tension reducing properties of SI-614 and to promote corneal epithelial wound healing by binding SI-614 to the fibronectin that occurs on corneal epithelial defects to promote epithelial cell growth. Through these actions, SI-614 is expected to restore the tear film and corneal structure to their normal state and improve symptoms associated with dry eye. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

HU007: Huons

HU007 is a combination of cyclosporine, an anti-inflammatory component, and trehalose, a tear film protection component, to minimize eye surface irritation such as burning sensation by lowering the concentration of cyclosporine to less than half than that of existing treatments. In addition, it is an ophthalmic agent developed to suppress the destruction of each conjunctival epithelial cells caused by drying by combining trehalose preparations and to see the combined treatment effect for dry eyes. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

A197: Aramis Biosciences

A197 is a novel topical agent that targets the immunopathogenesis of dry eye disease. It has a unique mechanism of action compared to existing dry eye treatments. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

INV 102: Invirsa, Inc.

INV 102 is an ophthalmic eye drop being developed by Invirsa, Inc. Invirsa’s lead candidate is a naturally-occurring, small molecule that modulates the activity of p53, the central protein responsible for regulating the DNA damage response. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

iVIEW 1001: IVIEW Therapeutics

iVIEW 1001 is a TRPM8 agonist drug being developed by iVIEW Therapeutics, Inc. to treat dry eye diseases. IVIEW 1001 is a TRPM8 agonist, which means it stimulates the transient receptor potential melastatin 8 (TRPM8) receptors in the eyelid margin. This stimulation sends a perception of coolness, reducing ocular discomfort and potentially increasing tear secretion. Currently, the drug is in the Phase I/II stage of development to treat Dry Eye Disease.

Further product details are provided in the report……..

Dry Eye Disease: Therapeutic Assessment

This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dry Eye Disease

There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. Phase III include, Alcon, Seikagaku Corporation, and Huons.

Phases

DelveInsight’s report covers around 60+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dry Eye Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Eye Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Eye Disease drugs.

Dry Eye Disease Report Insights

Dry Eye Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Dry Eye Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Dry Eye Disease drugs?

How many Dry Eye Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Dry Eye Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Alcon

Seikagaku Corporation

Huons

Aramis Biosciences

Invirsa, Inc.

IVIEW Therapeutics

Seinda Pharmaceutical

Serentrix

EyeD Pharma

SELAGINE

Theratome Bio

Alchemedicine

Key Products

AR-15512

SI-614

HU007

A197

INV 102

iVIEW 1001

SY-201

SER-114

HydraD

SLG-100

Thera 102

Dry eye disease therapeutic

Please Note: It will take 2-3 business days to complete the report upon order confirmation.